Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference
November 08 2017 - 7:00AM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced
that Rick Fair, President and CEO, is scheduled
to present a corporate overview at the Jefferies
2017 London Healthcare Conference on Wednesday, November
15 at 9:20 a.m. GMT in London, UK.
A live webcast of the presentation may be accessed from
the News & Events section of the Bellicum website. An
archived version of the webcast will be available for replay for at
least two weeks following the event.
About Bellicum Pharmaceuticals Bellicum is
a clinical stage biopharmaceutical company focused on discovering
and developing cellular immunotherapies for cancers and orphan
inherited blood disorders. Bellicum is using its proprietary
Chemical Induction of Dimerization (CID) technology platform to
engineer and control components of the immune system. Bellicum is
developing next-generation product candidates in some of the most
important areas of cellular immunotherapy, including allogeneic
hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR
cell therapies. More information can be found
at www.bellicum.com.
Investors: Bellicum Pharmaceuticals, Inc. Alan
Musso, CFO 832-384-1116 amusso@bellicum.com
Media: BMC Communications Brad
Miles646-513-3125 bmiles@bmccommunications.com
Source: Bellicum Pharmaceuticals
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024